Cargando…

Phase II trial of the antiangiogenic agent IM862 in metastatic renal cell carcinoma

IM862 is a naturally occurring dipeptide (L-glu-L-trp) with immunomodulatory and antiangiogenic properties. A significant anticancer activity has been reported recently in AIDS-related Kaposi's sarcoma, a tumour of endothelial cell origin. The high vascularity and responsiveness to immunotherap...

Descripción completa

Detalles Bibliográficos
Autores principales:	Deplanque, G, Madhusudan, S, Jones, P H, Wellmann, S, Christodoulos, K, Talbot, D C, Ganesan, T S, Blann, A, Harris, A L
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2004
Materias:	Clinical
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2409952/ https://www.ncbi.nlm.nih.gov/pubmed/15354209 http://dx.doi.org/10.1038/sj.bjc.6602126

Ejemplares similares

862. Spatial Distribution of HIV Transmission in Ethiopia and Characteristics of HIV Clusters
por: Ying, Roger, et al.
Publicado: (2018)

A novel gene ZNF862 causes hereditary gingival fibromatosis
por: Wu, Juan, et al.
Publicado: (2022)

Novel concepts of antiangiogenic therapies in metastatic renal cell cancer
por: Pichler, Renate, et al.
Publicado: (2017)

Effect of standard chemotherapy and antiangiogenic therapy on plasma markers and endothelial cells in colorectal cancer
por: Ramcharan, K S, et al.
Publicado: (2014)

Gaia Data Release 3 - Exploring and mapping the diffuse interstellar band at 862 nm
por: Schultheis, M., et al.
Publicado: (2023)

Incidence of chest wall deformity in 15,862 students in the province of Sivas, Türkiye
por: Katrancioglu, Ozgur, et al.
Publicado: (2023)

POS-862 PREVALENCE AND FACTORS ASSOCIATED WITH RHABDOMYOLYSIS IN COVID-19 PATIENTS: AN OBSERVATIONAL STUDY
por: Mboliassa, M.F., et al.
Publicado: (2022)

Oral Side Effects in Patients with Metastatic Renal Cell Carcinoma Receiving the Antiangiogenic Agent Pazopanib—Report of Three Cases
por: Papadopoulou, Erofili, et al.
Publicado: (2022)

Inhibitory effect on expression of angiogenic factors by antiangiogenic agents in renal cell carcinoma
por: Sasamura, H, et al.
Publicado: (2002)

Combination antiangiogenesis therapy with marimastat, captopril and fragmin in patients with advanced cancer
por: Jones, P H, et al.
Publicado: (2004)

Clinical benefit of antiangiogenic therapy in advanced and metastatic chondrosarcoma
por: Jones, Robin L., et al.
Publicado: (2017)

Comparison of prognostic factors in patients in phase I trials of cytotoxic drugs vs new noncytotoxic agents
por: Han, C, et al.
Publicado: (2003)

Angiogenesis and antiangiogenic agents in cervical cancer
por: Tomao, Federica, et al.
Publicado: (2014)

Circulating Plasma Biomarkers for TSU-68, an Oral Antiangiogenic Agent, in Patients with Metastatic Breast Cancer
por: Yoo, Changhoon, et al.
Publicado: (2016)

PPARα Ligands as Antitumorigenic and Antiangiogenic Agents
por: Pozzi, Ambra, et al.
Publicado: (2008)

862 Alcohol-Impregnated Disinfectant Caps Reduce The Rate Of Central-Line Associated Bloodstream Infections And Nosocomial Bacteremia
por: Shelly, Mark, et al.
Publicado: (2014)

862. Impact of Caregiver Health on Pediatric Healthcare-Associated Viral Respiratory Infections (HAVRIs): A Retrospective Study
por: Paquette, Maude, et al.
Publicado: (2020)

Risk profile for antiangiogenic agent-related osteonecrosis of the jaws
por: Caminha, Raquel D’Aquino Garcia, et al.
Publicado: (2019)

A phase II study of bryostatin 1 in metastatic malignant melanoma.
por: Propper, D. J., et al.
Publicado: (1998)

Safety profiles of current antiangiogenic therapies for metastatic colorectal cancer
por: Fuloria, Jyotsna
Publicado: (2012)

Enhanced efficacy of sitravatinib in metastatic models of antiangiogenic therapy resistance
por: Dolan, Melissa, et al.
Publicado: (2019)

Reply: Metronomic chemotherapy with cyclophosphamide and dexamethasone in patients with metastatic carcinoma of the prostate
por: Khan, O A, et al.
Publicado: (2012)

Eribulin combined with antiangiogenic agents in women with HER2-negative metastatic breast cancer: a retrospective multicenter study
por: Jiang, Mingxia, et al.
Publicado: (2023)

Antiangiogenic activity of aplidine, a new agent of marine origin
por: Taraboletti, G, et al.
Publicado: (2004)

DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents
por: O'Connor, J P B, et al.
Publicado: (2007)

Pulmonary cavitation in patients with thyroid cancer receiving antiangiogenic agents
por: Datar, Saumil, et al.
Publicado: (2020)

A phase II trial of a multi-agent oral antiangiogenic (metronomic) regimen in children with recurrent or progressive cancer
por: Robison, Nathan J, et al.
Publicado: (2014)

Neoadjuvant antiangiogenic therapy reveals contrasts in primary and metastatic tumor efficacy
por: Ebos, John ML, et al.
Publicado: (2014)

Relationship between hypoxia and response to antiangiogenic therapy in metastatic colorectal cancer
por: Ulivi, Paola, et al.
Publicado: (2016)

Metastatic Renal Medullary and Collecting Duct Carcinoma in the Era of Antiangiogenic and Immune Checkpoint Inhibitors: A Multicentric Retrospective Study
por: Guillaume, Zoé, et al.
Publicado: (2022)

Antiangiogenic tyrosine kinase inhibitors and immunotherapy as first-line treatment for metastatic renal cell carcinoma: is there an increased risk of hypothyroidism?
por: Roviello, Giandomenico, et al.
Publicado: (2021)

The efficacies and biomarker investigations of antiangiogenic agents and PD-1 inhibitors for metastatic soft tissue sarcoma: A multicenter retrospective study
por: Liu, Zhiyong, et al.
Publicado: (2023)

Phase II study of second-line therapy with DTIC, BCNU, cisplatin and tamoxifen (Dartmouth regimen) chemotherapy in patients with malignant melanoma previously treated with dacarbazine
por: Propper, D J, et al.
Publicado: (2000)

862. Machine Learning to Differentiate Group A Streptococcal (GAS) from Non-GAS Pharyngitis Using a Custom Smartphone App
por: Hamdy, Rana F, et al.
Publicado: (2023)

UPARANT is an effective antiangiogenic agent in a mouse model of rubeosis iridis
por: Locri, Filippo, et al.
Publicado: (2019)

Contemporary Updates on Clinical Trials of Antiangiogenic Agents in the Treatment of Glioblastoma Multiforme
por: Kochar, Arshneel Singh, et al.
Publicado: (2018)

Antiangiogenic therapy
por: Avitabile, T
Publicado: (2010)

DNA Methylation Biomarkers Predict Progression-Free and Overall Survival of Metastatic Renal Cell Cancer (mRCC) Treated with Antiangiogenic Therapies
por: Peters, Inga, et al.
Publicado: (2014)

Imaging Response of Antiangiogenic and Immune-Oncology Drugs in Metastatic Renal Cell Carcinoma (mRCC): Current Status and Future Challenges
por: Fournier, Laure, et al.
Publicado: (2017)

Antiangiogenic Drug-Induced Proteinuria as a Prognostic Factor in Metastatic Colorectal Cancer
por: Moisuc, Diana Cornelia, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_781asn13tndlq270nf8q0fon4e